Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTI-0102 in MELAS
2023-506723-28-00Phase 2Completed
- Sponsor
- Thiogenesis Therapeutics
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in mitochondrial encephalomyopathies comparing TTI-0102 with Placebo (2 arms). Primary endpoints: Change in functional capacity and Safety and tolerability. Started Dec 2024; status: completed.
02
Drugs
cysteamine-pantetheine disulfide
03
Conditions
mitochondrial encephalomyopathies
Beyond the preview
Go deeper on 2023-506723-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506723-28-00.